Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 650.90 INR
Change Today -11.20 / -1.69%
Volume 748.0K
As of 2:31 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

cipla ltd (CIPLA) Snapshot

Open
666.00
Previous Close
662.10
Day High
669.00
Day Low
647.25
52 Week High
03/10/15 - 752.85
52 Week Low
06/2/14 - 381.20
Market Cap
522.6B
Average Volume 10 Days
1.9M
EPS TTM
14.71
Shares Outstanding
803.0M
EX-Date
08/11/15
P/E TM
44.2x
Dividend
2.00
Dividend Yield
0.31%
Current Stock Chart for CIPLA LTD (CIPLA)

Related News

No related news articles were found.

cipla ltd (CIPLA) Related Businessweek News

No Related Businessweek News Found

cipla ltd (CIPLA) Details

Cipla Limited manufactures and sells pharmaceutical and personal care products in India and internationally. The company offers active pharmaceutical ingredients; and formulations in therapeutic areas, such as allergy, analgesic, anti malarial, anti-infectives, cardiology, dermatology and cosmeceuticals, diabetology, gastroenterology, HIV-AIDS, hormones and steroids, iron chelators, musculoskeletal, neuropsychiatry, nutritional and ophthalmic products, oncology, respiratory, urology, and women’s health, as well as steroids and hormones. It also provides veterinary products for various animals, including companion, equine, general care, live stock, and poultry. In addition, the company offers inhaled medication and devices comprising metered dose inhalers with dose indicators, dry powder inhalers, nasal sprays, nebulisers, non-electrostatic spacers, and infant and baby masks. It exports raw materials, intermediates, prescription drugs, OTC drugs, and veterinary products to approximately 170 countries worldwide. Cipla Limited was founded in 1935 and is based in Mumbai, India.

Founded in 1935

cipla ltd (CIPLA) Top Compensated Officers

Managing Director, Global Chief Executive Off...
Total Annual Compensation: 137.5M
Whole-Time Director, Member of Mergers & Acqu...
Total Annual Compensation: 12.0M
Compensation as of Fiscal Year 2014.

cipla ltd (CIPLA) Key Developments

Cipla Limited Announces Resignation of Rajesh Garg, Director Chief Financial Officer, Effective from June 12, 2015

Cipla Limited has announced that at the Board meeting held on May 29, 2015, a separation agreement is being entered into between Mr. Rajesh Garg and the company under which Mr. Rajesh Garg will demit office as a director, whole-time director and Chief Financial Officer of the company with effect from June 12, 2015.

Cipla Limited Reports Audited Standalone and Consolidated Earnings Results for the Fourth Quarter and Year Ended March 31, 2015

Cipla Limited reported audited standalone and consolidated earnings results for the fourth quarter and year ended March 31, 2015. For the quarter, on standalone basis, net sales were of INR 260.7 million against INR 221.17 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 28.2 million against INR 27.7 million a year ago. Profit before tax was INR 28.7 million against INR 34.6 million a year ago. Net profit after tax was INR 21.4 million or INR 2.65 diluted per share against INR 27.7 million or INR 3.44 diluted per share a year ago. For the year, on standalone basis, net sales were of INR 968.3 million against INR 911.2 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 152.8 million against INR 166.6 million a year ago. Profit before tax was INR 153.997 million against INR 181.834 million a year ago. Net profit after tax was INR 118.1 million or INR 14.66 diluted per share against INR 138.8 million or INR 17.27 diluted per share a year ago. For the quarter, on consolidated basis, net sales were of INR 298.1 million against INR 244.314 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 37.197 million against INR 30.427 million a year ago. Profit before tax was INR 38.981 million against INR 34.768 million a year ago. Net profit after tax was INR 28.679 million or INR 3.22 diluted per share against INR 27.238 million or INR 3.24 diluted per share a year ago. EBITDA grew by 24% to INR 5,080 million, up from INR 4,090 million. For the year, on consolidated basis, net sales were of INR 1,088.241 million against INR 982.580 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 165.699 million against INR 176.041 million a year ago. Profit before tax was INR 165.425 million against INR 188.004 million a year ago. Net profit after tax was INR 125.422 million or INR 14.66 diluted per share against INR 141.666 million or INR 17.27 diluted per share a year ago.

Cipla Ltd Recommends Dividend for the Year 2014-15, Dispatch/Credit on or After September 01, 2015

Cipla Ltd. has informed that the Board of Directors of the company at its meeting held on May 29, 2015 has recommended payment of dividend of INR 2 per equity share (face value INR 2 per equity share) for the year 2014-15. The dividend, subject to the approval of shareholders, will be dispatched/credited on or after September 01, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CIPLA:IN 650.90 INR -11.20

CIPLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 1,380 INR +19.30
Cadila Healthcare Ltd 1,838 INR -30.60
Divi's Laboratories Ltd 1,828 INR +1.40
Dr Reddy's Laboratories Ltd 3,505 INR -33.85
Torrent Pharmaceuticals Ltd 1,230 INR +7.35
View Industry Companies
 

Industry Analysis

CIPLA

Industry Average

Valuation CIPLA Industry Range
Price/Earnings 44.1x
Price/Sales 4.8x
Price/Book 4.8x
Price/Cash Flow 30.8x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CIPLA LTD, please visit www.cipla.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.